Molecular Biomarkers of Response to Radiation Therapy in Breast Cancer

Phase

N/A

Condition

Cancer

Breast Cancer

Treatment

N/A

Clinical Study ID

NCT06648148

DCIS-2019

Ages 18-75
Female

Study Summary

The purpose of this study is to identify potential genetic and other molecular biomarkers of response to radiation therapy in breast cancer that may help to personalize breast cancer radiation treatment in the future.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Breast cancer patients with DCIS with an indication for adjuvant radiation therapy

Exclusion

Exclusion Criteria:

Any specific systemic oncological therapy

Study Design

November 01, 2019

December 31, 2029

Study Description

Monocentric prospective clinical study including DCIS patients treated at the Institute of Oncology Ljubljana. Patients treated with adjuvant radiotherapy and without systemic therapy are eligible for the study.

Adverse events of radiation treatment will be assessed after radiotherapy and during 5-year follow up and classified according to Common Terminology Criteria for Adverse Events v5.0.

Molecular biomarkers will be assessed before radiotherapy, after radiotherapy and during follow up. DNA will be isolated from whole blood samples obtained before radiation treatment. Circulating biomarkers will be isolated from plasma samples before treatment, after treatment and during follow-up. Written informed consent will be obtained from all included patients and the study design was approved by the National Medical Ethics Committee.

Connect with a study center

Institute of Oncology Ljubljana
Ljubljana, 1000
Slovenia
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.